Does Keflex Cover Gram-Negative Bacteria?
Keflex (cephalexin) provides limited coverage against gram-negative bacteria, being effective only against a narrow spectrum of common community-acquired gram-negative organisms, but it is NOT appropriate for serious gram-negative infections or hospital-acquired infections.
Spectrum of Gram-Negative Coverage
According to the FDA drug label, cephalexin is active against only specific gram-negative organisms 1:
- Escherichia coli
- Haemophilus influenzae
- Klebsiella pneumoniae
- Moraxella catarrhalis
- Proteus mirabilis
Critical Limitations
Cephalexin has NO activity against:
- Pseudomonas species
- Acinetobacter calcoaceticus
- Most strains of Enterobacter species
- Morganella morganii
- Proteus vulgaris 1
This is a crucial distinction—cephalexin is a first-generation cephalosporin with predominantly gram-positive coverage and only modest activity against select gram-negative pathogens.
Clinical Context and Appropriate Use
When Cephalexin May Be Acceptable for Gram-Negative Coverage:
Community-acquired, uncomplicated infections where susceptible organisms are likely:
- Uncomplicated urinary tract infections caused by E. coli, Proteus mirabilis, or Klebsiella pneumoniae 1, 2
- Mild community-acquired skin infections where gram-negative involvement is minimal 3
When Cephalexin is INADEQUATE:
Do not use cephalexin for:
- Hospital-acquired infections (require broader gram-negative coverage) 4
- Severe or complicated infections requiring reliable gram-negative coverage 4
- Intra-abdominal infections (even mild cases require metronidazole combination and broader coverage) 5
- Any infection where Pseudomonas or resistant gram-negatives are suspected 6
Comparative Effectiveness
Research demonstrates cephalexin's limited gram-negative activity compared to other cephalosporins:
- Only 42.5% of gram-negative bacilli were sensitive to cephalexin, compared to 91.2% for cefotaxime 7
- Cephalexin-resistant gram-negative organisms (those requiring >200 μg/mL for inhibition) persist despite treatment, particularly in catheterized patients 8
- Newer oral cephalosporins like cefaclor show 4- to 16-fold greater activity against gram-negatives than cephalexin 9, 10
Resistance Considerations
Important caveat: Even for the limited gram-negative organisms cephalexin covers, increasing resistance is a concern. Studies show that 39-57.5% of common gram-negative isolates may be resistant to cephalexin 7. This makes culture and susceptibility testing essential when using cephalexin for suspected gram-negative infections 1.
Clinical Algorithm for Decision-Making
Use cephalexin for gram-negative coverage ONLY when:
- Infection is community-acquired AND uncomplicated
- Suspected organism is E. coli, Proteus mirabilis, or Klebsiella pneumoniae
- Patient has no risk factors for resistant organisms
- Culture and susceptibility can be obtained to confirm appropriateness
Choose alternative antibiotics when:
- Hospital-acquired infection
- Severe or complicated infection
- Risk factors for ESBL-producing organisms or other resistant pathogens
- Need for Pseudomonas coverage
- Polymicrobial infection likely
For mild-to-moderate community-acquired infections requiring broader gram-negative coverage, guidelines recommend amoxicillin-clavulanate or ceftriaxone/cefotaxime combinations instead 5. For severe infections with gram-negative concerns, third/fourth-generation cephalosporins, fluoroquinolones, or carbapenems are preferred 4, 6.